Amelanotic melanoma: The great masquerader

Koch, Susan E.; Lange, Julie R.

doi:10.1067/mjd.2000.103981

Cited by 154 publications

(143 citation statements)

References 14 publications

Supporting

Mentioning

134

Contrasting

Unclassified

Order By: Relevance

“…1 Cheung et al 2 defined amelanotic melanoma as being unsuspected clinically and with melanin in less than 5% of the tumour cells. Because the diagnosis was not suspected clinically, he noted that excisional biopsies were seldom performed, and that if undertaken, transection of the melanoma was common.…”

Section: Discussionmentioning

confidence: 99%

Amelanotic melanoma masquerading as a pyogenic granuloma: caution warranted

Chan

et al. 2014

Hong Kong Med J

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Amelanotic melanoma masquerading as a pyogenic granuloma: caution warranted

Chan

et al. 2014

Hong Kong Med J

View full text Add to dashboard Cite

“…A la IHQ expresan tirosinasa y factor de transcripción asociado a microftalmia (MITF), lo que sugiere que las células tumorales mantienen el linaje melanocítico. 7 (Figura 8a, 8b, 8c y 8d).…”

Section: Histopatologíaunclassified

Formas cutáneas y mucosas infrecuentes de melanoma. Parte II.

Deck

González

et al. 2018

Rev. chil. dermatol

View full text Add to dashboard Cite

ResumenSe han descrito varios subtipos infrecuentes de melanoma maligno en la literatura médica. A pesar de su baja frecuencia -que no suele superar el dos por ciento en varias series de melanoma -es muy importante reconocerlos precozmente pues un diagnóstico tardío está asociado a un muy mal pronóstico. En esta segunda parte incluiremos: melanoma verrugoso, melanoma polipoideo, melanoma hipomelanótico y amelanótico, melanoma folicular, melanoma spitzoide, melanoma con diferenciación no melanocítica.Palabras clave: melanoma maligno; piel; subtipos; melanoma maligno cutáneo. summaRySeveral infrequent subtypes of malignant melanoma have been described in the medical literature. Although their low frequency -less than two percent in various series of melanoma -it is very important to early recognize them because late diagnosis is associated with a very poor prognosis. In this second part we will include: verrucous melanoma, polypoid melanoma, hypomelanotic and amelanotic melanoma, follicular melanoma, spitzoid melanoma and non-melanocytic differentiation melanoma. L a mayoría de las series clínicas que reportan datos epidemiológicos de melanoma maligno (MM) describen frecuentemente sólo al melanoma de extensión superficial, melanoma nodular, melanoma léntigo maligno (MLM) y melanoma lentiginoso acral. Otras variedades de MM por lo general se incluyen como "otros", representando en promedio menos del 2% del total de los MM, con un rango de frecuencia entre 0,8 y 3,2% en las diferentes series. 1Sin embargo, es de gran relevancia el reconocimiento de estos subtipos de MM, ya que en la mayoría de los casos su diagnóstico tardío está asociado a etapas clínicas avanzadas de mal pronóstico. En esta segunda parte describiremos las siguientes variantes inusuales de melanoma: melanoma verrugoso, melanoma polipoideo, melanoma hipomelanótico y amelanótico, melanoma folicular, melanoma spitzoide, melanoma con diferenciación no melanocítica. melanoma veRRugosoEl melanoma verrugoso (MV) se semeja clínicamente a una queratosis seborreica, representando un gran desafío diagnóstico.2 Los MV, denominados también melanomas queratosis seborreica-like, constituyen el 0,7% del total de las queratosis seborreicas extirpadas y sólo el 50% de ellas tenían sospecha clínica de melanoma. Se requiere una alta sospecha clínica para biopsiar lesiones presuntamente benignas. 3 epidemiología Constituye el 3,2% del total de MM. Ocurren generalmente en cara, tronco y extremidades en hombres mayores de 50 años.

show abstract

“…These particles have high linear energy transfer radiation and lethally damage DNA when they penetrate a cell nucleus (1)(2)(3). The number of 10 B atoms incorporated into tumor cells is a critical factor that determines the specific, powerful killing effect of BNCT. It is reported that 15 to 30 Ag 10 B/g must be present in tumors and low levels in normal tissue, and that a sufficient number of thermal neutrons must reach a tumor for BNCT to be successful (4,5).…”

Section: Introductionmentioning

confidence: 99%

“…Thermal neutrons are captured by the 10 B atom, resulting in the emission of linear recoiling a-particles and 7 Li nuclei, with respective traveling ranges of f9 and f5 Am. These particles have high linear energy transfer radiation and lethally damage DNA when they penetrate a cell nucleus (1)(2)(3).…”

Section: Introductionmentioning

confidence: 99%

Improvement of the Tumor-Suppressive Effect of Boron Neutron Capture Therapy for Amelanotic Melanoma by Intratumoral Injection of the Tyrosinase Gene

et al. 2006

View full text Add to dashboard Cite

Boron neutron capture therapy (BNCT) is successful when there is a sufficient 10 B concentration in tumor cells. In melanoma, 10 B-para-boronophenylalanine (BPA) accumulation is proportional to melanin-producing activity. This study was done to confirm enhancement of the tumor-suppressive effect of BNCT on amelanotic melanoma by intratumoral injection of the tyrosinase gene. D178 or FF amelanotic melanomas were implanted s.c. in Syrian hamsters. One group of D178-or FF-bearing hamsters (TD178 or TFF group) received intratumoral injections of pcDNA-Tyrs constructed as a tyrosinase expression plasmid. The other hamsters (pD178 and pFF groups) were injected with pUC119, and control hamsters (D178 and FF groups) only with transfection reagents. All the groups underwent immunofluorescence analysis of tyrosinase expression and BPA biodistribution studies. BNCT experiments were done at the Kyoto University Research Reactor. Tyrosinase expression increased in the tumors of the TD178 and TFF groups but remained the same in the pD178 and pFF groups. Tumor boron concentrations in the TD178 and TFF groups increased significantly (TD178: 49.7 F 12.6 versus D178: 27.2 F 4.9 Mg/g, P < 0.0001; TFF: 30.7 F 6.6 versus FF: 13.0 F 4.7 Mg/g, P<0.0001). The BNCT tumor-suppressive effect was marked in the TD178 and TFF groups. In vivo transfection with the tyrosinase gene increased BPA accumulation in the tumors, the BNCT tumor-suppressive effect on amelanotic melanoma being significantly enhanced. These findings suggest a potential new clinical strategy for the treatment of amelanotic melanoma with BNCT. (Cancer Res 2006; 66(7): 3747-53)

show abstract

Amelanotic melanoma: The great masquerader

Cited by 154 publications

References 14 publications

Amelanotic melanoma masquerading as a pyogenic granuloma: caution warranted

Amelanotic melanoma masquerading as a pyogenic granuloma: caution warranted

Formas cutáneas y mucosas infrecuentes de melanoma. Parte II.

Improvement of the Tumor-Suppressive Effect of Boron Neutron Capture Therapy for Amelanotic Melanoma by Intratumoral Injection of the Tyrosinase Gene

Contact Info

Product

Resources

About